Search
Search results
318 results found
Daniel Ardeljan
Todd Golub
Todd Golub is director of the Broad Institute of MIT and Harvard, and a founding core member of the institute. He is also a member of the faculty of the Dana-Farber Cancer Institute and Harvard Medical School. Golub is a world-renowned physician-scientist who pioneered the application of genomics to...
About
Assistant to the Director Caitlin Ingelfinger +1 (617) 714-7350 trgoffice@broadinstitute.org Assistant to the Director Lee O'Neil trgoffice@broadinstitute.org Senior Laboratory Manager Maria Cecilia Saberi msaberi@broadinstitute.org Inquiries regarding open positions: TRGapplications@broadinstitute...
News & Events
Map shows how cancer cells spread through the body Broad@15 Talk Series; The March Toward Cancer Precision Medicine 09/2019
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Ebert, B. L., N. Galili, P. Tamayo, J. Bosco, R. Mak, J. Pretz, S. Tanguturi, et al. 2008. “An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome”. PLoS Med 5: e35.
Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Enache, O. M., V. Rendo, M. Abdusamad, D. Lam, D. Davison, S. Pal, N. Currimjee, et al. 2020. “Cas9 Activates the P53 Pathway and Selects for P53-Inactivating Mutations”. Nat Genet 52: 662-68.
Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Enache, O. M., V. Rendo, M. Abdusamad, D. Lam, D. Davison, S. Pal, N. Currimjee, et al. 2020. “Author Correction: Cas9 Activates the P53 Pathway and Selects for P53-Inactivating Mutations”. Nat Genet 52: 748-49.
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., D. S. Neuberg, J. Staunton, M. L. Loh, C. Huard, S. C. Raimondi, F. G. Behm, et al. 2002. “Gene Expression Signatures Define Novel Oncogenic Pathways in T Cell Acute Lymphoblastic Leukemia”. Cancer Cell 1: 75-87.
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Fuchs, B. C., Y. Hoshida, T. Fujii, L. Wei, S. Yamada, G. Y. Lauwers, C. M. McGinn, et al. 2014. “Epidermal Growth Factor Receptor Inhibition Attenuates Liver Fibrosis and Development of Hepatocellular Carcinoma”. Hepatology 59: 1577-90.